Is It Possible to Prevent Symptom Recurrence After Transurethral Resection for Hunner Lesion?

To the Editor:

The debilitating pelvic pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) is challenging to treat [1-3]. Transurethral resection and cauterization (TUR-C) is performed to treat patients with Hunner lesions [4]. However, several recent studies have shown that TUR-C alone did not exhibit significant therapeutic effects in patients with IC/BPS [5]; many patients experienced symptom recurrence, although symptom improvement was evident after TUR-C in the short term [6-8]. Bladder instillation therapy refers to the direct introduction of medication into the bladder, and it is a common treatment modality for patients with IC/BPS [8]. Instillation therapy has been shown to be efficacious, but this treatment has never been used to prevent the recurrence of symptoms after TUR-C in patients with Hunner-type IC/BPS. Therefore, we evaluated the preventive effect of additional hyaluronic acid and chondroitin sulfate (HA/CS) instillation therapy after TUR-C.

The study enrolled patients aged 18 years or more who were unresponsive to first-line noninvasive treatments (e.g., oral drugs considered to be standard treatments, such as pentosan polysulfate and amitriptyline). In order to enroll definitive IC/BPS patients, we used strict criteria and included IC/BPS patients who had a visual analogue scale (VAS) pain score >4 and total scores >13 on the pelvic pain and urgency/frequency (PUF) questionnaire and >12 on the O’Leary-Sant IC symptom index (ICSI)/problem index (ICPI). Hunner lesions were confirmed by cystoscopy. During TUR-C, the Hunner lesions were removed and cauterized to the maximal extent possible, using bipolar resectoscopy under general anesthesia. In order to assess the preventive effect of intravesical instillation of HA/CS, we divided the enrolled patients into a group that underwent TUR-C and a group that received additional instillation of HA/CS after TUR-C. These patients received once-weekly intravesical instillations of 40 mg of HA/CS diluted in 50 mL of saline solution for 4 weeks and once monthly for 2 months.

The primary endpoints were change in pelvic pain from baseline and the recurrence rate of pelvic pain, which was defined as a VAS score >4 points at 12 months. The VAS used a 0–10 scale (0=no pain and 10=worst possible pain), and an assessment at 12 months was compared with the baseline. The secondary endpoints were reduction in pain intensity, changes in ICSI/ICPI scores, and changes in urinary frequency based on a 3-day voiding diary from baseline to 6 months postoperatively. The safety assessment included the registration of all investigatorassessed adverse events. Analysis of covariance was performed to compare the 2 groups, with baseline levels as the covariate and using a modified baseline-observation-carried-forward approach to impute missing data for participants who dropped out due to lack of efficacy or adverse events and a last-observation-carried-forward strategy for patients who dropped out for other reasons. VAS score changes from baseline to 12 months postoperatively (the primary endpoint) were analyzed in the intention to treat population, including all randomized patients, and in the per protocol population, including patients who completed the study without any major protocol violation or receiving any grade A/B recommended treatment for IC/BPS, according to the European Association of Urology criteria.

Fig. 1 shows a flow diagram of the study. A total 30 patients were screened, including 15 for TUR-C alone and 15 for TURC with additional HA/CS instillation, with a mean age of 61.4 years (range, 49–72 years). There were 7 patients in whom TUR-C alone was discontinued before the end of the study due to dissatisfaction with treatment (n=2), noncompliance with the protocol (n=3), and loss to follow-up (n=2). Seven other patients who had TUR-C with additional instillation therapy did not finish the study due to dissatisfaction with treatment (n=3), noncompliance with the protocol (n=2), and loss to follow-up (n=2). All patients were randomized and included in the safety analysis. Overall, 16 patients—8 patients (53.3%) in the TUR-C alone group and 8 (53.3%) in the additional instillation group—finished the study. The 2 groups were well represented and well balanced in terms of baseline characteristics. Demographic and baseline clinical characteristics were comparable in the 2 groups at baseline (Table 1). The primary endpoints were change in pelvic pain and the recurrence rate at 12 months after treatment. The patients who underwent TUR-C alone showed a 75% recurrence rate at 12 months, whereas the patients who received additional HA/CS instillation therapy after TUR-C showed a recurrence rate of 25% at 12 months. This difference was significant (P<0.001) (Fig. 2). A significant reduction in pain intensity was observed at 6 months in both treatment groups versus baseline (P<0.001); however, the difference in the mean VAS score between the 2 groups did not reach statistical significance at that time. Nonetheless, it reached statistical significance at 12 months (3.8 vs. 1.6, P=0.017). The secondary endpoint was the reduction in PUF scores (–6.8 vs. –8.1, respectively), total ICSI/ICPI scores (–11.1 vs. –11.7, respectively), and urinary frequency (–7.1 vs. –8.5, respectively) at 6 months. These reductions were not significantly different between the treatment groups (Fig. 3). No patients showed symptom recurrence, which was defined as a VAS score >4 points, at 6 months.

Fig. 1.

Diagram of patient selection. IC/BPS, interstitial cystitis/bladder pain syndrome; TUR-C, transurethral resection and cauterization; group 1, TUR-C only; group 2, TUR-C and instillation; VAS, visual analogue scale; PUF, pelvic pain and urgency/frequency; IC-Q, Interstitial Cystitis-Questionnaire.

Table 1.

Baseline characteristics

Characteristic	Total (n=16)	Group 1 (n=8)	Group 2 (n=8)	P-value
Age (yr)	61.4 ± 7.0	59.8 ± 7.4	63.0 ± 6.6	0.391
VAS	7.3 ± 1.7	7.6 ± 1.3	7.0 ± 2.0	0.482
PUF	20.6 ± 6.3	21.8 ± 5.8	19.3 ± 6.1	0.461
IC-Q	25.9 ± 9.7	27.6 ± 8.4	24.2 ± 11.1	0.507
Urinary frequency	18.5 ± 2.2	17.8 ± 2.5	19.1 ± 1.7	0.275

Values are presented as mean±standard deviation.

TUR-C, transurethral resection and cauterization; group 1, TUR-C only; group 2, TUR-C and instillation; VAS, visual analogue scale; PUF, pelvic pain and urgency/frequency; IC-Q, Interstitial Cystitis-Questionnaire.

Fig. 2.

Comparison of mean visual analogue scale (VAS) score (P=0.037) (A), rate of recurrence (P=0.066) (B), and recurrence-free rate (P=0.033) (C) between the 2 groups over 12 months of follow-up. TUR-C, transurethral resection and cauterization; group 1, TUR-C only; group 2, TUR-C and instillation.

Fig. 3.

Comparison of clinical outcomes between the 2 groups at 6 months of follow-up. (A) Pelvic pain and urgency/frequency (PUF), (B) Interstitial Cystitis-Questionnaire (IC-Q), and (C) urinary continence (times/day). TUR-C, transurethral resection and cauterization; group 1, TUR-C only; group 2, TUR-C and instillation.

The cause of IC/BPS, which is a chronic and severe inflammatory bladder disease, remains unknown [9,10]. HA/CS instillation therapy has shown an encouraging response rate, as highlighted in several recent trials and meta-analyses [11]. Although these treatment strategies have shown good efficacy, a definitive limitation remains; namely, after the alleviation of severe symptoms by treatment, many patients experience symptom recurrence. The results of the present study confirm that both treatments led to reduced pain scores and urinary frequency, as well as improved bladder capacity, in both groups at 6 months after treatment was initiated, and there was no significant difference in efficacy between the 2 groups. No patients showed symptom recurrence at that time. However, there was a significant difference in the rates of symptom recurrence between the 2 groups at 12 months after treatment initiation.

We have reported that TUR-C was efficacious for Hunnertype IC/BPS, although the effect decreased gradually over time [7]. Generally, instillation treatments are used as a third-line therapy, and are reserved for patients in whom conservative care and oral medication have failed. Unfortunately, several studies have shown that TUR-C only or bladder instillation therapy alone did not exhibit significant long-term therapeutic effects, even though some short-term improvements were evident [12,13]. Many treatment tools for IC/BPS have been introduced and evaluated, but no trials have investigated the prevention of symptom recurrence. Therefore, our results might have clinical significance. Severe inflammatory lesions were removed through TUR-C, and defects in the protective barrier of the glycosaminoglycan layer were repaired through HA/CS instillation therapy. Additional instillation therapy after TUR-C might decrease symptom recurrence through the replacement of urothelium throughout the bladder. Some reports have demonstrated that denudation of the entire urothelium of the bladder was found in Hunner-type IC/BPS [14,15]. Additional instillation therapy decreased symptom recurrence, but not Hunner lesions recurrence. We performed cystoscopy at 6 and 12 months after TUR-C in order to evaluate whether Hunner lesions had recurred. Unfortunately, there was no significant difference between the 2 groups regarding the recurrence of Hunner lesions.

The limitations of this study included the small sample size and short follow-up period. In conclusion, additional HA/CS instillation therapy after TUR-C was effective for preventing symptom recurrence in Hunner-type IC/BPS patients.